Marinomed Biotech AG announced the results of the Annual General Meeting held on June 15, 2022. The shareholders approved all resolutions proposed by the Management and Supervisory Boards with a large majority. As proposed by the Supervisory Board, the AGM elected two new members to the Supervisory Board, Dr. Lackner and Ulrich Kinzel, for a term of office until 2027.

Dr. Elisabeth Lackner is an entrepreneur and well-networked pharmaceutical and biotechnology executive with more than 20 years of experience combining growth, business strategy & innovation, marketing, business development and international expansion, regulatory and operations in life science with full P&L responsibility, thereof 10+ years CEO. She excels through the combination of an entrepreneurial mindset with high creativity and cultural agility combined with extensive experience in leading multicultural teams. Dr. Lackner is member on several boards, and respected consultant and speaker in the industry. Ulrich Kinzel is a Managing Director at the advisory firm goetzpartners, responsible for the healthcare industry group.

Previously, he was a founding partner of Code Securities, London, a specialist life science investment bank acquired by Nomura in 2005. Ulrich has extensive financing and capital markets experience and has advised leading international healthcare, life sciences and digital health companies in more than 70 successful M&A and ECM transactions, including cross-border European, US and Asian public and private takeovers as well as IPOs and secondary offerings on all major European Stock Exchanges.